[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514215":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":106,"collaborators":108,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":123,"maxAge":23,"enrollmentInfo":124,"targetDuration":23,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":140,"overallStatus":46,"whyStopped":23,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,15],{"label":9,"type":6,"description":10,"interventionNames":11},"Cervical Cancer","* Patients will have blood and tumor collected at various time points throughout participation in the study.\n* Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI.",[12,13,14],"Other: Tumor collection via biopsy","Other: Blood collection","Device: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)",{"label":16,"type":6,"description":10,"interventionNames":17},"Pancreatic Cancer",[12,13,14],[19,24,28],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Tumor collection via biopsy","Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.\n\nPancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence.",[9,16],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Blood collection","Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.\n\nPancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence",[9,16],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DEVICE","Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)","Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.\n\nPancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.\n\nThe imaging will be performed when possible.",[9,16],[34],"DBSI MRI",[36],{"name":37,"affiliation":5,"role":38},"Cliff Robinson, M.D.","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":23,"email":43},"CONTACT","314-362-8567","clifford.robinson@wustl.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-90.19789,38.62727,{"lat":56,"lon":55},[59,60,61,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94,96,98,100,102,104],{"name":37,"role":41,"phone":42,"phoneExt":23,"email":43},{"name":37,"role":38,"phone":23,"phoneExt":23,"email":23},{"name":62,"role":63,"phone":23,"phoneExt":23,"email":23},"Carl DeSelm, M.D., Ph.D.","SUB_INVESTIGATOR",{"name":65,"role":63,"phone":23,"phoneExt":23,"email":23},"Stephanie Markovina, M.D., Ph.D.",{"name":67,"role":63,"phone":23,"phoneExt":23,"email":23},"Julie Schwarz, M.D., Ph.D.",{"name":69,"role":63,"phone":23,"phoneExt":23,"email":23},"Jessika Contreras, M.D.",{"name":71,"role":63,"phone":23,"phoneExt":23,"email":23},"Dineo Khabele, M.D.",{"name":73,"role":63,"phone":23,"phoneExt":23,"email":23},"David DeNardo, Ph.D.",{"name":75,"role":63,"phone":23,"phoneExt":23,"email":23},"Hyun Kim, M.D.",{"name":77,"role":63,"phone":23,"phoneExt":23,"email":23},"Kian-Huat Lim, M.D.",{"name":79,"role":63,"phone":23,"phoneExt":23,"email":23},"Hua Li, Ph.D.",{"name":81,"role":63,"phone":23,"phoneExt":23,"email":23},"Albert Lai, Ph.D.",{"name":83,"role":63,"phone":23,"phoneExt":23,"email":23},"Philip Payne, Ph.D.",{"name":85,"role":63,"phone":23,"phoneExt":23,"email":23},"Doug Caruthers, M.S.",{"name":87,"role":63,"phone":23,"phoneExt":23,"email":23},"Esther Lu, Ph.D.",{"name":89,"role":63,"phone":23,"phoneExt":23,"email":23},"Lei Liu, Ph.D.",{"name":91,"role":63,"phone":23,"phoneExt":23,"email":23},"Andrea Hagemann, M.D.",{"name":93,"role":63,"phone":23,"phoneExt":23,"email":23},"Lindsay Kuroki, M.D.",{"name":95,"role":63,"phone":23,"phoneExt":23,"email":23},"Leslie Stuart Massad, M.D.",{"name":97,"role":63,"phone":23,"phoneExt":23,"email":23},"Carolyn McCourt, M.D.",{"name":99,"role":63,"phone":23,"phoneExt":23,"email":23},"Maggie Mullen, M.D.",{"name":101,"role":63,"phone":23,"phoneExt":23,"email":23},"Matthew Powell, M.D.",{"name":103,"role":63,"phone":23,"phoneExt":23,"email":23},"Brooke Sanders, M.D.",{"name":105,"role":63,"phone":23,"phoneExt":23,"email":23},"Premal Thaker, M.D.",{"type":107,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[109,112],{"name":110,"class":111},"National Cancer Institute (NCI)","NIH",{"name":113,"class":6},"The Foundation for Barnes-Jewish Hospital","100514215","microenvironment-tumor-effects-of-radiotherapy---comprehensive-radiobiology-assessment-trial-100514215",false,"NCT05975593","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)","METEOR-CRATR","Inclusion Criteria:\n\n* Confirmation of intent to receive radiotherapy for one of the following diagnoses:\n\n  * Cervical cancer\n  * Pancreatic cancer\n* ECOG performance status ≤ 2\n* At least 18 years old\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician","ALL","18 Years",{"count":125,"type":126},60,"ESTIMATED","INTERVENTIONAL",[129],"NA","This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.",[132,133,134,135,136,9,137,16,138,139],"Locally Advanced Cervical Carcinoma","Locally Advanced Cervical Cancer","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Carcinoma","Locally Advanced Pancreatic Cancer","Pancreas Cancer","Cancer of the Cervix","Cancer of the Pancreas",[141,142,143,144,145],"Radiotherapy","Chemotherapy","Cervical cancer","Pancreatic cancer","Biospecimen","2025-11-07",{"date":148,"type":149},"2025-11-12","ACTUAL",{"date":151,"type":149},"2024-01-11",{"date":153,"type":126},"2032-12-31",{"name":5,"class":6},1]